German medical cannabis company Avextra closed a funding round totaling more than 20 million euros ($21.5 million).
The Bensheim, Germany-based business said in a Wednesday news release that the funding round was comprised of equity instruments and convertible loan notes, all of which have been converted into common shares, giving the company a valuation of 100 million euros.
ADVERTISEMENT
Avextra is a vertically integrated manufacturer and developer of pharmaceutical-grade, cannabis-based medicines.
The privately owned company said the funding will accelerate clinical trials for certain medical cannabis treatments and help to expand its European distribution channels.
“The continued support from our existing shareholders along with the participation of new institutional investors and strategic partners in this most recent capital raise, in the midst of
Read full article on Marijuana Business Daily
